Third, the BEVAEL trial using bevacizumab plus gemcitabine and platinum in CDC and SMARCB1-deficient renal medullary carcinoma (RMC) reported an ORR of 39% with an mOS of 11 months (n = 26 of 34). The gene discussed is SMARCB1; the disease is kidney medullary carcinoma.